S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
NASDAQ:APGE

Apogee Therapeutics (APGE) Stock Price, News & Analysis

$27.94
-2.08 (-6.93%)
(As of 12/29/2023 ET)
Today's Range
$27.93
$31.62
50-Day Range
$15.00
$31.07
52-Week Range
$14.19
$33.08
Volume
266,106 shs
Average Volume
312,534 shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.83

Apogee Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
28.3% Upside
$35.83 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Apogee Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.70) to ($2.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

764th out of 950 stocks

Biological Products, Except Diagnostic Industry

136th out of 158 stocks


APGE stock logo

About Apogee Therapeutics Stock (NASDAQ:APGE)

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

APGE Stock Price History

APGE Stock News Headlines

Apogee Therapeutics (NASDAQ:APGE) Stock Price Up 2.5%
MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
Apogee Therapeutics (NASDAQ:APGE) Stock Price Up 6.6%
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month High at $25.85
MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
Apogee Therapeutics Inc APGE
See More Headlines
Receive APGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apogee Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APGE
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.83
High Stock Price Target
$43.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+28.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.42 billion
Optionable
Not Optionable
Beta
N/A
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Michael Thomas Henderson M.D. (Age 34)
    CEO & Director
    Comp: $369.71k
  • Dr. Carl Linden Dambkowski M.D. (Age 38)
    Chief Medical Officer
    Comp: $389.18k
  • Ms. Jane Pritchett V. Henderson (Age 57)
    Chief Financial Officer
  • Dr. Rebecca Dabora Ph.D. (Age 64)
    Chief Technical Officer
  • Ms. Noel Kurdi
    Vice President of Investor Relations
  • Mr. Matthew Batters J.D. (Age 47)
    General Counsel
  • Ms. Emily Cox
    VP & Head of People
  • Ms. Wendy Aspden-Curran
    Senior Vice President of Clinical Operations
  • Dr. Drew Badger Ph.D.
    Senior VP and Head of Regulatory Affairs & Toxicology
  • Ms. Monica Forbes (Age 47)
    Senior Vice President of Finance














APGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Apogee Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apogee Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APGE shares.
View APGE analyst ratings
or view top-rated stocks.

What is Apogee Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 12 month price targets for Apogee Therapeutics' shares. Their APGE share price targets range from $29.00 to $43.00. On average, they expect the company's stock price to reach $35.83 in the next twelve months. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for APGE
or view top-rated stocks among Wall Street analysts.

How have APGE shares performed in 2023?

Apogee Therapeutics' stock was trading at $21.23 at the start of the year. Since then, APGE stock has increased by 31.6% and is now trading at $27.94.
View the best growth stocks for 2023 here
.

When is Apogee Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our APGE earnings forecast
.

How were Apogee Therapeutics' earnings last quarter?

Apogee Therapeutics, Inc. (NASDAQ:APGE) released its earnings results on Monday, November, 13th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.08.

When did Apogee Therapeutics IPO?

(APGE) raised $282 million in an IPO on Friday, July 14th 2023. The company issued 17,650,000 shares at a price of $15.00-$17.00 per share.

When does Apogee Therapeutics' lock-up period expire?

Apogee Therapeutics' lock-up period expires on Wednesday, January 10th. Apogee Therapeutics had issued 17,650,000 shares in its initial public offering on July 14th. The total size of the offering was $300,050,000 based on an initial share price of $17.00. After the end of Apogee Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Apogee Therapeutics?

Shares of APGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APGE) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -